CAMP4 Therapeutics Corporation (CAMP) on Thursday said it has entered into a strategic research, collaboration and license agreement with GSK to develop antisense oligonucleotide (ASO) drug candidates targeting multiple genes linked to neurodegenerative and kidney diseases.
Under the terms of the agreement, CAMP4 will receive an upfront payment of $17.5 million. The company is also eligible for additional development and commercial milestone payments, as well as tiered royalties on future product sales.
CAMP4 will use its proprietary RAP Platform to identify regulatory RNAs controlling the expression of selected gene targets and to generate ASO candidates designed to increase target gene expression. GSK will be responsible for further development and commercialization of any ASO drug candidates arising from the collaboration.
"Protein under-expression plays a critical role in diseases such as neurodegenerative and kidney disease. Our collaboration with GSK, focused on the rapid identification of novel targets and potential ASO therapeutics that increase the expression of validated genetic targets, underscores the potential of our discovery platform to create transformational medicines for patients," said Josh Mandel-Brehm, President and Chief Executive Officer of CAMP4.
CAMP4 Therapeutics shares were down more than 5% in premarket trading after closing at $7.13 on Wednesday, up 1.7%.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.